Dailypharm Live Search Close

Will Osimertinib emerge as the standard of care

By Park, sang-jun | translator Kang, Shin-Kook

24.06.10 05:21:00

°¡³ª´Ù¶ó 0
LAURA study results presented at ASCO 2024

Osimertinib reduces the risk of disease progression and death by 84%

The LAURA trial, which evaluated osimertinib¡¯s effect in patients with unresectable Stage III EGFR-mutant non-small cell lung cancer who received chemoradiotherapy (CRT), was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The results were also concurrently published in NEJM.


#
The LAURA trial evaluated progression-free survival (PFS) in 216 patients with unresectable stage III EGFR-mutant NSCLC who received chemoradiotherapy (CRT). The patients were randomized to receive osimertinib or placebo.

The results showed a median PFS of 39.1 months and 5.6 months in the osimertinib and placebo arms, respectively, with an 84% reduction in the risk of dis

Park, sang-jun(lib6983@dailypharm.com)
If you want to see the full article, please JOIN US (click)